A Placebo-controlled Trial (Part 1) or Active-controlled (Part 2) of SABER Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy

Trial Profile

A Placebo-controlled Trial (Part 1) or Active-controlled (Part 2) of SABER Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Bupivacaine (Primary) ; Bupivacaine
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 22 Jun 2017 According to a DURECT Corporation media release, company expects to complete patient follow-up visits during the third quarter.
    • 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 May 2017 According to a DURECT Corporation media release, recent enrollment rates for the trial are ahead of schedule and support completion of dosing in the second quarter of 2017 and top-line results in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top